Focused On-demand Library for Germ cell nuclear acidic protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96QF7

UPID:

GCNA_HUMAN

Alternative names:

Acidic repeat-containing protein; Germ cell nuclear acidic peptidase; Germ cell nuclear antigen

Alternative UPACC:

Q96QF7; B9EG62

Background:

The Germ cell nuclear acidic protein, also known as Acidic repeat-containing protein, Germ cell nuclear acidic peptidase, and Germ cell nuclear antigen, plays a crucial role in maintaining genomic stability. It is instrumental in the clearance of DNA-protein cross-links (DPCs) through a SUMO-dependent recruitment to sites of DPCs, safeguarding germ cells and early embryos from damage. This protein is particularly adept at resolving topoisomerase II (TOP2A) DPCs, highlighting its significance in cellular repair mechanisms.

Therapeutic significance:

Linked to Spermatogenic failure, X-linked, 4, a male infertility disorder characterized by non-obstructive azoospermia or oligoasthenoteratozoospermia, the Germ cell nuclear acidic protein's understanding could pave the way for innovative therapeutic strategies. Its role in ensuring genomic stability by protecting germ cells suggests potential in treating infertility issues.